Novavax (NVAX) Is Now A Premier COVID Vaccine Company, Jefferies Thinks FDA EUA Possible
Tweet Send to a Friend
Jefferies analyst Kelechi Chikere reiterated a Buy rating and $200.00 price target on Novavax (NASDAQ: NVAX) after the company announced ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
